Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study

The safety of obinutuzumab, alone or with chemotherapy, was studied in a non-randomized, open-label, non-comparative, phase IIIb study (GREEN) in previously untreated or relapsed/refractory chronic lymphocytic leukemia. Patients received obinutuzumab 1000 mg alone or with chemotherapy (investigator’...

詳細記述

書誌詳細

主要な著者:	Véronique Leblond, Melih Aktan, Christelle M. Ferra Coll, Caroline Dartigeas, Jens Kisro, Marco Montillo, João Raposo, Jean-Louis Merot, Susan Robson, Ekaterina Gresko, Francesc Bosch, Stephan Stilgenbauer, Robin Foà
フォーマット:	Artigo
言語:	Inglês
出版事項:	Ferrata Storti Foundation 2018-11-01
シリーズ:	Haematologica
オンライン･アクセス:	https://haematologica.org/article/view/8667
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!